Applications of 2-[4-(1,3-Benzodioxol-5-Ylmethyl)Piperazin-1-Yl]Pyrimidine in Industrial Manufacturing

As a dedicated manufacturer of 2-[4-(1,3-Benzodioxol-5-Ylmethyl)Piperazin-1-Yl]Pyrimidine, we supply this advanced intermediate to a focused group of high-value chemical sectors. Our customers rely on its essential role in targeted synthesis routes, meeting stringent demands in regulated environments. Below, you will find detailed use-cases reflecting real-world downstream adoption, process details, and end market requirements.

1. Active Pharmaceutical Ingredient (API) Intermediate for Central Nervous System (CNS) Drug Development

This piperazine-derived intermediate forms a key building block in the multi-step synthesis of psychoactive and neuroprotective pharmaceuticals. Drug formulation teams incorporate it during the early condensation and cyclization phases to introduce the benzodioxolyl pharmacophore, critical for binding selectivity in CNS-active molecules. QC managers and production supervisors apply precise inline controls to monitor purity and batch consistency, ensuring batch records align with international submission dossiers.

Industry compliance standards

• ICH Q7 GMP for APIs
• FDA 21 CFR Part 211 for finished pharmaceuticals
• European Pharmacopoeia (Ph. Eur.) monograph guidance
• China NMPA Raw Material Drug Registration standards

Typical usage ratio

• 0.8%–2.3% molar ratio in core condensation steps, calculated based on target API batch size; adjustment informed by final pharmacophore incorporation yield

Downstream process integration

• Added post-piperazine alkylation as a limiting reagent in the stepwise assembly of CNS-active molecular scaffolds, before final hydrogenation and crystallization

Final product types

• Small molecule psychotropic drugs (e.g., anxiolytics, antipsychotics)
• Neurotransmitter reuptake inhibitors
• Cognitive disorder therapeutic agents

2. Intermediate for Antihistamine and Allergy Medication Synthesis

Formulation chemists in the allergy and respiratory drug sector employ this molecule’s piperazinyl pyrimidine core in coupling reactions to synthesize advanced antihistaminic agents. During the combinatorial phase, control systems track residual starting material to support clean downstream purification, maintaining compliance with allergy pharmaceutical impurity thresholds. Plant operations teams work closely to synchronize feedstock delivery, ensuring uninterrupted campaign production and consistent release quality.

Industry compliance standards

• US Pharmacopeia (USP) monographs relevant to antihistamines
• EMA’s Guideline on the Chemistry of Active Substances
• Good Manufacturing Practice (EU GMP Part II)
• Japanese PMDA specifications for chemical drug substances

Typical usage ratio

• 1.1–2.0 molar equivalents per coupling cycle, adapted to selected R-group substitute yields and impurity profile management

Downstream process integration

• Charged at the nucleophilic substitution stage onto pre-activated aromatic halides, with reaction monitoring for completion prior to downstream neutralization and API isolation

Final product types

• Prescription and OTC antihistamine tablets
• Allergy syrup formulations
• Non-sedating H1 receptor antagonist finished products

3. Fine Chemical Intermediate for Targeted Oncology Research Compounds

R&D groups synthesizing new heterocyclic compounds for cancer research use this benzodioxole-piperazine structure to introduce targeted binding motifs in lead-stage molecules. Reaction engineers automate metered additions in microreactor or batch reactors, maintaining tight pH and temperature ranges to maximize coupling fidelity and patentable molecular diversity. Analytical teams closely document structural verification using NMR and HPLC to comply with preclinical filing protocols.

Industry compliance standards

• OECD Good Laboratory Practice (GLP) for non-clinical safety studies
• USP General Chapter <797> for chemical processing
• ISO 9001:2015 for research reagent manufacturing
• Material transfer compliance for in-licensed compounds

Typical usage ratio

• 0.3–0.7 mmol per mmol of nucleophilic acceptor in high-throughput library synthesis; precise ratio determined by lead optimization route and desired analog output

Downstream process integration

• Charged during late-stage amination or palladium-catalyzed cross-coupling reactions, typically before final deprotection and column purification steps

Final product types

• Oncology research candidate libraries
• Preclinical targeted cancer therapeutics
• Trial-scale molecular probe substances

4. Synthesis Intermediate in Veterinary Pharmaceuticals

Veterinary medicine manufacturers select this compound’s pyrimidinyl core for targeted synthesis of anti-parasitic and CNS modulators in companion animal and livestock health applications. Chemists integrate the intermediate during early glycosylation reactions, tracking input-output yields to optimize cost efficiencies while upholding batch traceability. Regulatory and QC departments reference animal-use monographs and perform extra residue analysis to meet export standards for medicated feed and injectables.

Industry compliance standards

• VICH GL3 (GMP for active ingredients)
• Ph. Eur. monographs for veterinary raw materials
• US FDA CVM guidance
• Australia APVMA standards for chemical inputs

Typical usage ratio

• 0.9%–1.8% by weight in active precursor preparation stages, fine-tuned based on desired spectrum of antiparasitic activity and pharmacokinetic objectives

Downstream process integration

• Used as an early-stage condensation input in the synthesis of pyrimidine-based veterinary APIs, ahead of formulation into dosage-controlled injectable solutions and medicated feed additives

Final product types

• Antiparasitic veterinary injectables
• Oral anti-anxiety medications for animals
• Medicated feed premixes for poultry and livestock